<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294734</url>
  </required_header>
  <id_info>
    <org_study_id>116678</org_study_id>
    <nct_id>NCT02294734</nct_id>
  </id_info>
  <brief_title>An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition
      to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic
      Obstructive Pulmonary Disease (COPD). Additionally study will also assess safety,
      tolerability and pharmacokinetic data. The total duration of the study will be 13-14 weeks
      including screening, treatment period and a follow up visit. Subjects will receive once daily
      study treatment administration starting on Day 1. Study is planned to recruit approximately
      120 subjects such that approximately 100 subjects complete the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2015</start_date>
  <completion_date type="Actual">April 25, 2016</completion_date>
  <primary_completion_date type="Actual">February 19, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>siVaw is a measure of the volume in an individual's airway corrected for their lobar volume derived from the high resolution computed tomography (HRCT). It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>iVaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>iRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>siRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>Change from Baseline in lung lobar volumes was measured at functional residual volume (FRC) and total lung capacity (TLC) scan conditions. Data was collected at longitudinal time points: Day 12 &amp; Day 28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points the baseline is screening. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>Imaging trachea length and diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length and diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment</measure>
    <time_frame>Baseline, Day 12 and Day 28</time_frame>
    <description>Imaging trachea length/diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length/diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>From start of IP through the Study Phase (84 days post-dose) (assessed up to follow-up duration of approximately 100 days)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were collected from the start of study treatment until the follow-up contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Hematology Parameters</measure>
    <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 Days)</time_frame>
    <description>Hematology parameter included Hematocrit (HCT), Hemoglobin (HB), Lymphocytes (LC), Platelet Count (PC), Total Neutrophils (TN), and White Blood Cell (WBC) count at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Clinical Chemistry Parameters</measure>
    <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
    <description>Clinical Chemistry parameters included Alanine Amino Transferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Calcium (Ca), Glucose, Potassium (K), Sodium (Na), and Total Bilirubin (TBL) at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Vital Signs</measure>
    <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
    <description>Vital signs included high and low diastolic and systolic blood presure (BP), and high and low heart rate (HR). Vital signs outside the range of potential clinical importance are presented at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline . Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)</measure>
    <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
    <description>12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Clinically non-significant (CN) and Clinically significant (CS) abnormal ECG measurements are presented for Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose</measure>
    <time_frame>Pre-dose, 5 min, 3 hrs and 24 hrs</time_frame>
    <description>Plasma samples were collected at pre-dose, 5 minutes (min), 3 hrs, and 24 hrs post-dose on Day 1. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Pharmacokinetic (PK) Population: all participants in the Safety Population for whom a PK sample was obtained and analyzed. Safety Population comprises of all participants who were randomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment</measure>
    <time_frame>Pre-dose Day 12, Day 28, Day 56, and Day 84</time_frame>
    <description>Trough concentrations are presented for Pre-dose Day 12, Pre-dose Day 28, Pre-dose Day 56, and Pre-dose Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily</measure>
    <time_frame>Baseline, Day 28, and Day 84</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second. A triplicate FEV1 measurement were taken daily in the morning before dose administration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily</measure>
    <time_frame>Baseline, Day 28, and Day 84</time_frame>
    <description>PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>DLco is diffusing capacity o f the lungs for carbon monoxide and is defined as the extent to which oxygen passes from the air sacs of the lungs into the blood. KCO is the carbon monoxide transfer coefficient. It is an index of the efficiency of alveolar transfer of carbon monoxide. Baseline is defined as the assessment on Day 2 and percent change from Baseline is the post-Baseline value minus Baseline value/100. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>TLC is the maximum amount of air that can fill the lungs. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>Residual volume is a lung volume representing the amount of air left in the lungs after a forced exhalation. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>Functional residual capacity is the volume of air present in the lungs at the end of passive expiration. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>sRaw is the measure of specific resistance. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).Note: values mentioned as 95% confidence interval below are in fact values of 95% Credible Interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84</measure>
    <time_frame>Baseline, Day 28 and Day 84</time_frame>
    <description>The chronic obstructive pulmonary disease (COPD) assessement test (CAT) and Modified Medical Research Council (MMRC) Dyspnea Scale were completed at the indicated timepoints: Baseline, Day 28 and Day 84. CAT and MMRC scales are prestned as: 1.I never cough/I cough all the time 2.I have no phelgm in my chest at all/My chest is completely full of phelgm 3. My chest does not feel tight at all/My chest feels very tight 4.Walk up hilll or stairs not breathless/Walk up hill or stairs very breathless 5. Not limited doing any home activities/Very limited doing any home activities 6. Confident leaving home/No confident leaving home 7. I sleep soundly/I don't sleep soundly because of my lung condition and 8. I have lots of energy/I have no energy at all. Baseline is defined as the assessment on Day 1. Score 0 indicates not troubled with breathlessness to 4:too breathless. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Failures</measure>
    <time_frame>13 weeks</time_frame>
    <description>Treatment failure types are presented as: recurrent exacerbations, prolonged treatment of current exacerbation (beyond 14 days), additional treatment with systemic / oral corticosteroids and / or antibiotics, and requirement for invasive mechanical ventilation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GSK2269557 repeat dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo repeat dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557</intervention_name>
    <description>Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily</description>
    <arm_group_label>GSK2269557 repeat dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dry powder for inhalation via DISKUS 'device'</description>
    <arm_group_label>Matching placebo repeat dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 40 and 80 years of age inclusive, at the time of signing the informed consent

          -  The subject has a confirmed and established diagnosis of COPD, as defined by the
             global initiative for chronic Obstructive Lung Disease (GOLD) guidelines for at least
             6 months prior to entry.

          -  The subject has a post-bronchodilator FEV1/Forced Vital Capacity (FVC) &lt; 0.7 and FEV1
             &lt;= 80 % of predicted (Predictions should be according to the European Community of
             Coal and Steel [ECCS] equations), documented in the last 5 years.

          -  Disease severity: Acute exacerbation of COPD requiring an escalation in therapy to
             include corticosteroid and antibiotics. Acute exacerbation to be confirmed by an
             experienced physician and represent a recent change in at least two major and one
             minor symptoms, one major and two minor symptoms, or all 3 major symptoms. Major
             symptoms: subjective increase in dyspnea, increase in sputum volume, and change in
             sputum colour. Minor symptoms: cough, wheeze and sore throat.

          -  The subject is a smoker or an ex-smoker with a smoking history of at least 10 pack
             years (pack years = [cigarettes per day smoked/20 x number of years smoked])

          -  Body weight &gt;= 45 kilogram (kg) and body mass index (BMI) within the range 18 - 32
             kg/metered squared (m^2) (inclusive).

          -  Male

          -  Female subject : is eligible to participate if she is not pregnant (as confirmed by a
             negative urine human chorionic gonadotrophin [hCG] test), not lactating, and at least
             one of the following conditions applies:

        Non-reproductive potential defined as: Pre-menopausal females with one of the following:
        documented tubal ligation, documented hysteroscopic tubal occlusion procedure with
        follow-up confirmation of bilateral tubal occlusion, hysterectomy and documented bilateral
        oophorectomy. Postmenopausal defined as 12 months of spontaneous amenorrhea (in
        questionable cases a blood sample with simultaneous follicle stimulating hormone [FSH] and
        estradiol levels consistent with menopause (refer to laboratory reference ranges for
        confirmatory levels). Females on hormone replacement therapy (HRT) and whose menopausal
        status is in doubt will be required to use one of the highly effective contraception
        methods if they wish to continue their HRT during the study. Otherwise, they must
        discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

        Reproductive potential and agrees to follow one of the options listed below in the GSK
        Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive
        Potential (FRP) requirements from 30 days prior to the first dose of study medication and
        until completion of the follow-up visit.

        GlaxoSmithKline (GSK) Modified List of Highly Effective Methods for Avoiding Pregnancy in
        Females of Reproductive Potential (FRP):

        Contraceptive subdermal implant that meets the standard operating procedure (SOP)
        effectiveness criteria including a &lt;1% rate of failure per year, as stated in the product
        label.

        Intrauterine device or intrauterine system that meets the SOP effectiveness criteria
        including a &lt;1% rate of failure per year, as stated in the product label.

        Oral Contraceptive, either combined or progestogen alone. Injectable progestogen.
        Contraceptive vaginal ring. Percutaneous contraceptive patches. Male partner sterilization
        with documentation of azoospermia prior to the female subject's entry into the study, and
        this male is the sole partner for that subject.

        Male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository).

          -  Male subjects with female partners of child bearing potential must comply with the
             following contraception requirements from the time of first dose of study medication
             until after the completion of the follow up visit.

        Vasectomy with documentation of azoospermia. Male condom plus partner use of one of the
        contraceptive options below: Contraceptive subdermal implant that meets the SOP
        effectiveness criteria including a &lt;1% rate of failure per year, as stated in the product
        label. Intrauterine device or intrauterine system that meets the SOP effectiveness criteria
        including a &lt;1% rate of failure per year, as stated in the product label. Oral
        Contraceptive, either combined or progestogen alone or injectable progestogen.
        Contraceptive vaginal ring. Percutaneous contraceptive patches.

        These allowed methods of contraception are only effective when used consistently, correctly
        and in accordance with the product label. The investigator is responsible for ensuring that
        subjects understand how to properly use these methods of contraception.

          -  Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the consent form and in the study protocol.

        Exclusion Criteria:

          -  To avoid recruitment of subjects with a severe COPD exacerbation, the presence of any
             one of the following severity criteria will render the subject ineligible for
             inclusion in the study:

        Need for invasive mechanical ventilation (short term (&lt; 48hour) Non-invasive Ventilation
        (NIV) or Continuous Positive Airway Pressure [CPAP] is acceptable).

        Haemodynamic instability or clinically significant heart failure. Confusion.

          -  Subjects who have a history or current medical conditions or diseases that are not
             well controlled and, which as judged by the Investigator, may affect subject safety or
             influence the outcome of the study. (Note: Patients with adequately treated and well
             controlled concurrent medical conditions [e.g. hypertension or non-insulin dependent
             diabetes mellitus] are permitted to be entered into the study).

          -  Subject has a diagnosis of active tuberculosis, lung cancer, clinically overt
             bronchiectasis, pulmonary fibrosis, asthma or any other respiratory condition that
             might, in the opinion of the investigator, compromise the safety of the subject or
             affect the interpretation of the results.

          -  Alanine aminotransferase &gt;2x upper limit of normal (ULN) and bilirubin &gt;1.5xULN
             (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct
             bilirubin &lt;35%).

          -  A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the exclusion criteria, outside of the reference range for the
             population being studied may be included if the Investigator [in consultation with the
             GSK Medical Monitor if required] documents that the finding is unlikely to introduce
             additional risk factors and will not interfere with the study procedures.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  ECG indicative of an acute cardiac event (e.g. Myocardial Infarction) or demonstrating
             a clinically significant arrhythmia requiring treatment.

          -  QTcF &gt; 450 millisecond (msec) or QTcF &gt; 480 msec in subjects with Bundle Branch Block,
             based on single QTcF value.

          -  Subjects who have undergone lung volume reduction surgery.

          -  Subject is currently on chronic treatment with macrolides; long term oxygen therapy (&gt;
             15 hours/day).

          -  The subject has been on chronic treatment with anti-Tumour Necrosis Factor (anti-TNF),
             anti-Interleukin-1 (anti-IL1), or any other immunosuppressive therapy within 60 days
             prior to dosing.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of &gt;28 units for males or &gt;21 units for females. One unit is
             equivalent to 8 gram of alcohol: a half-pint ( equivalent to 240 milliliter [mL]) of
             beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.

          -  History of sensitivity to any of the study medications, or components thereof (such as
             lactose) or a history of drug or other allergy that, in the opinion of the
             investigator or Medical Monitor, contraindicates their participation.

          -  A known (historical) positive test for human immune virus (HIV) antibody.

          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
             result at screening or within 3 months prior to first dose of study treatment. NOTE:
             Because of the short window for screening, treatment with GSK2269557 may start before
             receiving the result of the hepatitis tests. If subsequently the test is found to be
             positive, the subject may be withdrawn, as judged by the Principal Investigator in
             consultation with the Medical Monitor.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within 56 days.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than 4 investigational medicinal products within 12 months prior to
             the first dosing day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erpent</city>
        <zip>5101</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kobenhavn</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense</city>
        <zip>5000 Odense C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050159</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105 077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>October 17, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional respiratory capacity</keyword>
  <keyword>High-resolution computed tomography</keyword>
  <keyword>GSK2269557</keyword>
  <keyword>acute exacerbation of COPD</keyword>
  <keyword>lung capacity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of a screening visit, a 12-week treatment period, and a 1-2 week post-treatment follow-up. The total duration of the study was 13-14 weeks including the screening visit.</recruitment_details>
      <pre_assignment_details>Approximately 120 participants with an acute exacerbation of chronic obstructive pulmonary disease (COPD) were randomized (1:1) to GSK 2269557 1000 micrograms (µg) and placebo such that approximately 100 participants complete the study. Participants were also stratified by whether they were willing and able to provide sputum samples at screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
        <group group_id="P2">
          <title>GSK2269557 1000 mcg</title>
          <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
        <group group_id="B2">
          <title>GSK2269557 1000 mcg</title>
          <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="7.88"/>
                    <measurement group_id="B2" value="65.6" spread="7.14"/>
                    <measurement group_id="B3" value="65.2" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White - White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
        <description>siVaw is a measure of the volume in an individual’s airway corrected for their lobar volume derived from the high resolution computed tomography (HRCT). It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>Intention to Treat (ITT) Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Imaging Airway Volume (siVaw), Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
          <description>siVaw is a measure of the volume in an individual’s airway corrected for their lobar volume derived from the high resolution computed tomography (HRCT). It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
          <population>Intention to Treat (ITT) Population excluding the subject with a pacemaker.</population>
          <units>Milliliter/Liter (mL/L)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC; Longitudinal; Lobes; RUL; D12 , n =54, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033" lower_limit="0.851" upper_limit="1.255"/>
                    <measurement group_id="O2" value="1.052" lower_limit="0.924" upper_limit="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RUL; D28 , n =56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.775" upper_limit="1.246"/>
                    <measurement group_id="O2" value="1.075" lower_limit="0.940" upper_limit="1.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.817" upper_limit="1.165"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.877" upper_limit="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.893" lower_limit="0.745" upper_limit="1.070"/>
                    <measurement group_id="O2" value="1.090" lower_limit="0.932" upper_limit="1.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RML; D12 , n =52, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.956" lower_limit="0.806" upper_limit="1.135"/>
                    <measurement group_id="O2" value="0.871" lower_limit="0.691" upper_limit="1.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RML; D28 , n=53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.853" lower_limit="0.677" upper_limit="1.075"/>
                    <measurement group_id="O2" value="1.006" lower_limit="0.867" upper_limit="1.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" lower_limit="0.684" upper_limit="1.204"/>
                    <measurement group_id="O2" value="1.115" lower_limit="0.885" upper_limit="1.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.871" lower_limit="0.652" upper_limit="1.164"/>
                    <measurement group_id="O2" value="1.167" lower_limit="0.975" upper_limit="1.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.051" lower_limit="0.885" upper_limit="1.248"/>
                    <measurement group_id="O2" value="1.087" lower_limit="0.892" upper_limit="1.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.806" upper_limit="1.242"/>
                    <measurement group_id="O2" value="1.199" lower_limit="0.999" upper_limit="1.438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" lower_limit="0.956" upper_limit="1.151"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.921" upper_limit="1.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.999" lower_limit="0.892" upper_limit="1.118"/>
                    <measurement group_id="O2" value="0.993" lower_limit="0.910" upper_limit="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" lower_limit="0.858" upper_limit="1.010"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.933" upper_limit="1.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" lower_limit="0.891" upper_limit="1.077"/>
                    <measurement group_id="O2" value="1.012" lower_limit="0.938" upper_limit="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" lower_limit="0.862" upper_limit="1.051"/>
                    <measurement group_id="O2" value="1.018" lower_limit="0.934" upper_limit="1.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.973" lower_limit="0.893" upper_limit="1.061"/>
                    <measurement group_id="O2" value="1.014" lower_limit="0.942" upper_limit="1.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.924" lower_limit="0.811" upper_limit="1.052"/>
                    <measurement group_id="O2" value="0.977" lower_limit="0.878" upper_limit="1.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.832" upper_limit="1.034"/>
                    <measurement group_id="O2" value="0.967" lower_limit="0.872" upper_limit="1.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.830" upper_limit="1.035"/>
                    <measurement group_id="O2" value="1.023" lower_limit="0.925" upper_limit="1.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.987" lower_limit="0.863" upper_limit="1.129"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.893" upper_limit="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" lower_limit="0.815" upper_limit="1.159"/>
                    <measurement group_id="O2" value="1.014" lower_limit="0.916" upper_limit="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.920" lower_limit="0.829" upper_limit="1.020"/>
                    <measurement group_id="O2" value="1.015" lower_limit="0.918" upper_limit="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.031" lower_limit="0.925" upper_limit="1.149"/>
                    <measurement group_id="O2" value="1.050" lower_limit="0.939" upper_limit="1.173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.034" lower_limit="0.893" upper_limit="1.198"/>
                    <measurement group_id="O2" value="1.064" lower_limit="0.958" upper_limit="1.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.897" upper_limit="1.066"/>
                    <measurement group_id="O2" value="1.055" lower_limit="0.953" upper_limit="1.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal;Region; Upper; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" lower_limit="0.809" upper_limit="1.120"/>
                    <measurement group_id="O2" value="1.004" lower_limit="0.891" upper_limit="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Upper; D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.918" lower_limit="0.769" upper_limit="1.096"/>
                    <measurement group_id="O2" value="1.066" lower_limit="0.939" upper_limit="1.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Lower; D12 , n=54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.819" upper_limit="1.194"/>
                    <measurement group_id="O2" value="1.065" lower_limit="0.878" upper_limit="1.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Lower; D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.952" lower_limit="0.772" upper_limit="1.172"/>
                    <measurement group_id="O2" value="1.150" lower_limit="0.979" upper_limit="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region;Central; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" lower_limit="0.886" upper_limit="1.060"/>
                    <measurement group_id="O2" value="1.021" lower_limit="0.963" upper_limit="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal;Region; Central; D28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.992" lower_limit="0.918" upper_limit="1.071"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.958" upper_limit="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Distal; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.963" lower_limit="0.801" upper_limit="1.158"/>
                    <measurement group_id="O2" value="1.027" lower_limit="0.889" upper_limit="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Distal D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.939" lower_limit="0.778" upper_limit="1.134"/>
                    <measurement group_id="O2" value="1.098" lower_limit="0.959" upper_limit="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region;Total; D12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.970" lower_limit="0.881" upper_limit="1.068"/>
                    <measurement group_id="O2" value="1.018" lower_limit="0.955" upper_limit="1.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Total; D28 ,n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.911" upper_limit="1.074"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.959" upper_limit="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.899" upper_limit="1.088"/>
                    <measurement group_id="O2" value="1.001" lower_limit="0.929" upper_limit="1.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.962" lower_limit="0.878" upper_limit="1.054"/>
                    <measurement group_id="O2" value="1.007" lower_limit="0.925" upper_limit="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.967" lower_limit="0.889" upper_limit="1.051"/>
                    <measurement group_id="O2" value="1.011" lower_limit="0.949" upper_limit="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.019" lower_limit="0.920" upper_limit="1.128"/>
                    <measurement group_id="O2" value="1.028" lower_limit="0.924" upper_limit="1.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.868" upper_limit="1.157"/>
                    <measurement group_id="O2" value="1.039" lower_limit="0.944" upper_limit="1.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.953" lower_limit="0.873" upper_limit="1.040"/>
                    <measurement group_id="O2" value="1.008" lower_limit="0.920" upper_limit="1.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.988" lower_limit="0.911" upper_limit="1.072"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.964" upper_limit="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.932" upper_limit="1.078"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.954" upper_limit="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.998" lower_limit="0.942" upper_limit="1.057"/>
                    <measurement group_id="O2" value="0.977" lower_limit="0.932" upper_limit="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.998" lower_limit="0.903" upper_limit="1.104"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.925" upper_limit="1.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" lower_limit="0.883" upper_limit="1.095"/>
                    <measurement group_id="O2" value="1.021" lower_limit="0.936" upper_limit="1.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.963" lower_limit="0.887" upper_limit="1.044"/>
                    <measurement group_id="O2" value="1.019" lower_limit="0.950" upper_limit="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.911" upper_limit="1.074"/>
                    <measurement group_id="O2" value="1.019" lower_limit="0.960" upper_limit="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.931" upper_limit="1.078"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.953" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.995" lower_limit="0.940" upper_limit="1.054"/>
                    <measurement group_id="O2" value="0.982" lower_limit="0.936" upper_limit="1.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RUL; D12 , n =58, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.048" lower_limit="0.951" upper_limit="1.154"/>
                    <measurement group_id="O2" value="0.976" lower_limit="0.912" upper_limit="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RUL; D28 , n =56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" lower_limit="0.927" upper_limit="1.179"/>
                    <measurement group_id="O2" value="0.979" lower_limit="0.908" upper_limit="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.043" lower_limit="0.933" upper_limit="1.166"/>
                    <measurement group_id="O2" value="1.007" lower_limit="0.936" upper_limit="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.078" lower_limit="0.922" upper_limit="1.260"/>
                    <measurement group_id="O2" value="1.027" lower_limit="0.947" upper_limit="1.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RML; D12 , n =57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.087" lower_limit="0.906" upper_limit="1.304"/>
                    <measurement group_id="O2" value="0.894" lower_limit="0.787" upper_limit="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RML; D28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.084" lower_limit="0.893" upper_limit="1.317"/>
                    <measurement group_id="O2" value="0.903" lower_limit="0.808" upper_limit="1.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.038" lower_limit="0.884" upper_limit="1.219"/>
                    <measurement group_id="O2" value="0.906" lower_limit="0.820" upper_limit="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.014" lower_limit="0.839" upper_limit="1.227"/>
                    <measurement group_id="O2" value="0.948" lower_limit="0.858" upper_limit="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LLL; D12 , n =57, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.074" lower_limit="0.917" upper_limit="1.258"/>
                    <measurement group_id="O2" value="0.934" lower_limit="0.844" upper_limit="1.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.075" lower_limit="0.901" upper_limit="1.282"/>
                    <measurement group_id="O2" value="0.993" lower_limit="0.891" upper_limit="1.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.040" lower_limit="0.978" upper_limit="1.105"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.940" upper_limit="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" lower_limit="0.949" upper_limit="1.097"/>
                    <measurement group_id="O2" value="0.981" lower_limit="0.925" upper_limit="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.971" lower_limit="0.908" upper_limit="1.039"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.956" upper_limit="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.022" lower_limit="0.961" upper_limit="1.088"/>
                    <measurement group_id="O2" value="1.001" lower_limit="0.950" upper_limit="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" lower_limit="0.962" upper_limit="1.113"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.933" upper_limit="1.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.933" upper_limit="1.086"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.956" upper_limit="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.029" lower_limit="0.948" upper_limit="1.116"/>
                    <measurement group_id="O2" value="0.934" lower_limit="0.870" upper_limit="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" lower_limit="0.933" upper_limit="1.116"/>
                    <measurement group_id="O2" value="0.932" lower_limit="0.877" upper_limit="0.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.904" upper_limit="1.063"/>
                    <measurement group_id="O2" value="1.008" lower_limit="0.942" upper_limit="1.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.022" lower_limit="0.940" upper_limit="1.112"/>
                    <measurement group_id="O2" value="0.932" lower_limit="0.871" upper_limit="0.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" lower_limit="0.897" upper_limit="1.078"/>
                    <measurement group_id="O2" value="0.944" lower_limit="0.884" upper_limit="1.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.962" lower_limit="0.881" upper_limit="1.051"/>
                    <measurement group_id="O2" value="1.027" lower_limit="0.980" upper_limit="1.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.024" lower_limit="0.939" upper_limit="1.117"/>
                    <measurement group_id="O2" value="0.967" lower_limit="0.908" upper_limit="1.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.933" upper_limit="1.125"/>
                    <measurement group_id="O2" value="0.972" lower_limit="0.907" upper_limit="1.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" lower_limit="0.911" upper_limit="1.062"/>
                    <measurement group_id="O2" value="1.017" lower_limit="0.970" upper_limit="1.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal;Region; Upper; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.031" lower_limit="0.935" upper_limit="1.137"/>
                    <measurement group_id="O2" value="0.983" lower_limit="0.922" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Upper; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.046" lower_limit="0.918" upper_limit="1.191"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.928" upper_limit="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Lower; D12 , n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.051" lower_limit="0.909" upper_limit="1.215"/>
                    <measurement group_id="O2" value="0.924" lower_limit="0.840" upper_limit="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Lower; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.037" lower_limit="0.879" upper_limit="1.223"/>
                    <measurement group_id="O2" value="0.974" lower_limit="0.883" upper_limit="1.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region;Central; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.001" lower_limit="0.971" upper_limit="1.033"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.971" upper_limit="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal;Region; Central; D28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.006" lower_limit="0.979" upper_limit="1.033"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.972" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Distal; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.043" lower_limit="0.931" upper_limit="1.168"/>
                    <measurement group_id="O2" value="0.949" lower_limit="0.883" upper_limit="1.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Distal D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" lower_limit="0.902" upper_limit="1.197"/>
                    <measurement group_id="O2" value="0.982" lower_limit="0.910" upper_limit="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region;Total; D12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" lower_limit="0.969" upper_limit="1.051"/>
                    <measurement group_id="O2" value="0.982" lower_limit="0.958" upper_limit="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Total; D28 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.967" upper_limit="1.044"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.964" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.028" lower_limit="0.969" upper_limit="1.090"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.944" upper_limit="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" lower_limit="0.953" upper_limit="1.095"/>
                    <measurement group_id="O2" value="0.984" lower_limit="0.932" upper_limit="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.985" lower_limit="0.922" upper_limit="1.054"/>
                    <measurement group_id="O2" value="1.003" lower_limit="0.962" upper_limit="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" lower_limit="0.943" upper_limit="1.105"/>
                    <measurement group_id="O2" value="0.954" lower_limit="0.897" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.996" lower_limit="0.916" upper_limit="1.083"/>
                    <measurement group_id="O2" value="0.960" lower_limit="0.899" upper_limit="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" lower_limit="0.899" upper_limit="1.052"/>
                    <measurement group_id="O2" value="1.018" lower_limit="0.977" upper_limit="1.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.972" upper_limit="1.029"/>
                    <measurement group_id="O2" value="0.997" lower_limit="0.975" upper_limit="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.981" upper_limit="1.030"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.972" upper_limit="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.004" lower_limit="0.981" upper_limit="1.028"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.984" upper_limit="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.960" upper_limit="1.095"/>
                    <measurement group_id="O2" value="0.972" lower_limit="0.922" upper_limit="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.008" lower_limit="0.936" upper_limit="1.086"/>
                    <measurement group_id="O2" value="0.972" lower_limit="0.919" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.912" upper_limit="1.050"/>
                    <measurement group_id="O2" value="1.011" lower_limit="0.973" upper_limit="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.973" upper_limit="1.037"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.967" upper_limit="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.004" lower_limit="0.976" upper_limit="1.032"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.965" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" lower_limit="0.970" upper_limit="1.025"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.984" upper_limit="1.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>60.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.21</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>74.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.48</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>13.98</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RML; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.92</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RML; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>80.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.79</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>51.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>90.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>54.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.45</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>62.95</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.86</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.16</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.51</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.59</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>61.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.63</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.No</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.02</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>53.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>70.84</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>74.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>65.43</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal;Region; Upper; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Upper; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Lower; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>91.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Lower; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>76.81</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region;Central; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>67.01</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal;Region; Central; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.91</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Distal; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.47</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Distal D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>72.17</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region;Total; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>74.38</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Total; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>53.85</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.02</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>92.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>54.65</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.93</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>77.57</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>77.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>78.42</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>44.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>52.79</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.51</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region; Distal; SCRD28 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>93.16</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>73.70</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.04</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>52.58</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>15.85</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.69</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>52.25</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.48</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.12</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RML; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>16.95</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RML; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>50.40</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>7.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LLL; D12 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>56.35</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>4.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>24.79</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>77.08</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>23.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>18.58</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>44.94</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.21</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.60</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>3.23</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>20.83</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.60</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>7.90</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>23.39</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>76.16</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>22.54</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal;Region; Upper; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>58.17</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Upper; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.22</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Lower; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>55.85</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Lower; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>25.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region;Central; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>18.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal;Region; Cetral; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>8.12</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Distal; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>57.39</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Distal D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>10.00</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region;Total; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>29.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Total; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>12.63</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; SCRD28 The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>69.92</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>33.63</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>41.38</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>24.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>29.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>7.13</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.91</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>21.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>24.49</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>55.52</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
        <description>iVaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Imaging Airways Volume: iVaw, Measured at FRC and TLC Scan Conditions, Presented in Longitudinal and Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
          <description>iVaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. Data was collected at longitudinal time points: Screening, Day 12 &amp; Day 28 and at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points and SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>Milliliter (mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC; Longitudinal; Lobes; RUL; D12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.020" lower_limit="0.838" upper_limit="1.242"/>
                    <measurement group_id="O2" value="1.058" lower_limit="0.930" upper_limit="1.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RUL; D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" lower_limit="0.755" upper_limit="1.220"/>
                    <measurement group_id="O2" value="1.121" lower_limit="0.965" upper_limit="1.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LUL; D12 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.951" lower_limit="0.789" upper_limit="1.145"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.866" upper_limit="1.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LUL; D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.876" lower_limit="0.727" upper_limit="1.055"/>
                    <measurement group_id="O2" value="1.108" lower_limit="0.938" upper_limit="1.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RML; D12 , n =53, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" lower_limit="0.746" upper_limit="1.098"/>
                    <measurement group_id="O2" value="0.869" lower_limit="0.694" upper_limit="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RML; D28 , n=53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.835" lower_limit="0.655" upper_limit="1.064"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.870" upper_limit="1.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RLL; D12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" lower_limit="0.669" upper_limit="1.182"/>
                    <measurement group_id="O2" value="1.119" lower_limit="0.892" upper_limit="1.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; RLL; D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.850" lower_limit="0.634" upper_limit="1.140"/>
                    <measurement group_id="O2" value="1.177" lower_limit="0.977" upper_limit="1.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LLL; D12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" lower_limit="0.853" upper_limit="1.212"/>
                    <measurement group_id="O2" value="1.067" lower_limit="0.881" upper_limit="1.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Lobes; LLL; D28 ,n =54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.784" upper_limit="1.226"/>
                    <measurement group_id="O2" value="1.187" lower_limit="0.992" upper_limit="1.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" lower_limit="0.942" upper_limit="1.137"/>
                    <measurement group_id="O2" value="1.006" lower_limit="0.927" upper_limit="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" lower_limit="0.872" upper_limit="1.091"/>
                    <measurement group_id="O2" value="1.027" lower_limit="0.938" upper_limit="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.861" upper_limit="0.997"/>
                    <measurement group_id="O2" value="1.018" lower_limit="0.948" upper_limit="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" lower_limit="0.870" upper_limit="1.048"/>
                    <measurement group_id="O2" value="1.010" lower_limit="0.932" upper_limit="1.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.933" lower_limit="0.846" upper_limit="1.029"/>
                    <measurement group_id="O2" value="1.035" lower_limit="0.946" upper_limit="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" lower_limit="0.902" upper_limit="1.068"/>
                    <measurement group_id="O2" value="1.029" lower_limit="0.956" upper_limit="1.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" lower_limit="0.798" upper_limit="1.027"/>
                    <measurement group_id="O2" value="0.970" lower_limit="0.872" upper_limit="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.907" lower_limit="0.807" upper_limit="1.020"/>
                    <measurement group_id="O2" value="0.972" lower_limit="0.876" upper_limit="1.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" lower_limit="0.833" upper_limit="1.032"/>
                    <measurement group_id="O2" value="1.031" lower_limit="0.933" upper_limit="1.139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" lower_limit="0.849" upper_limit="1.102"/>
                    <measurement group_id="O2" value="1.004" lower_limit="0.905" upper_limit="1.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" lower_limit="0.796" upper_limit="1.131"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.925" upper_limit="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.916" lower_limit="0.837" upper_limit="1.002"/>
                    <measurement group_id="O2" value="1.018" lower_limit="0.920" upper_limit="1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" lower_limit="0.898" upper_limit="1.108"/>
                    <measurement group_id="O2" value="1.031" lower_limit="0.935" upper_limit="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" lower_limit="0.869" upper_limit="1.182"/>
                    <measurement group_id="O2" value="1.054" lower_limit="0.954" upper_limit="1.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.922" upper_limit="1.061"/>
                    <measurement group_id="O2" value="1.061" lower_limit="0.962" upper_limit="1.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal;Region; Upper; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.933" lower_limit="0.789" upper_limit="1.104"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.882" upper_limit="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Upper; D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" lower_limit="0.749" upper_limit="1.077"/>
                    <measurement group_id="O2" value="1.079" lower_limit="0.943" upper_limit="1.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Lower; D12 , n=54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" lower_limit="0.798" upper_limit="1.166"/>
                    <measurement group_id="O2" value="1.058" lower_limit="0.878" upper_limit="1.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Lower; D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.931" lower_limit="0.751" upper_limit="1.153"/>
                    <measurement group_id="O2" value="1.151" lower_limit="0.978" upper_limit="1.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region;Central; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.945" lower_limit="0.863" upper_limit="1.035"/>
                    <measurement group_id="O2" value="1.016" lower_limit="0.961" upper_limit="1.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal;Region; Cetral; D28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" lower_limit="0.892" upper_limit="1.050"/>
                    <measurement group_id="O2" value="1.010" lower_limit="0.961" upper_limit="1.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Distal; D12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.939" lower_limit="0.779" upper_limit="1.132"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.883" upper_limit="1.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Distal D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.917" lower_limit="0.757" upper_limit="1.110"/>
                    <measurement group_id="O2" value="1.107" lower_limit="0.961" upper_limit="1.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region;Total; D12 n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.946" lower_limit="0.858" upper_limit="1.043"/>
                    <measurement group_id="O2" value="1.012" lower_limit="0.951" upper_limit="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Longitudinal; Region; Total; D28 ,n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" lower_limit="0.885" upper_limit="1.053"/>
                    <measurement group_id="O2" value="1.017" lower_limit="0.961" upper_limit="1.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" lower_limit="0.881" upper_limit="1.067"/>
                    <measurement group_id="O2" value="0.997" lower_limit="0.923" upper_limit="1.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.941" lower_limit="0.860" upper_limit="1.030"/>
                    <measurement group_id="O2" value="1.019" lower_limit="0.934" upper_limit="1.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" lower_limit="0.893" upper_limit="1.049"/>
                    <measurement group_id="O2" value="1.025" lower_limit="0.960" upper_limit="1.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.994" lower_limit="0.902" upper_limit="1.096"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.929" upper_limit="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.846" upper_limit="1.135"/>
                    <measurement group_id="O2" value="1.040" lower_limit="0.948" upper_limit="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" lower_limit="0.889" upper_limit="1.02"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.928" upper_limit="1.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964" lower_limit="0.891" upper_limit="1.044"/>
                    <measurement group_id="O2" value="1.016" lower_limit="0.967" upper_limit="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.908" upper_limit="1.054"/>
                    <measurement group_id="O2" value="1.007" lower_limit="0.966" upper_limit="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.950" upper_limit="1.053"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.946" upper_limit="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" lower_limit="0.882" upper_limit="1.074"/>
                    <measurement group_id="O2" value="1.003" lower_limit="0.923" upper_limit="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" lower_limit="0.862" upper_limit="1.070"/>
                    <measurement group_id="O2" value="1.030" lower_limit="0.944" upper_limit="1.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" lower_limit="0.897" upper_limit="1.039"/>
                    <measurement group_id="O2" value="1.030" lower_limit="0.961" upper_limit="1.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" lower_limit="0.891" upper_limit="1.045"/>
                    <measurement group_id="O2" value="1.014" lower_limit="0.963" upper_limit="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.908" upper_limit="1.054"/>
                    <measurement group_id="O2" value="1.008" lower_limit="0.964" upper_limit="1.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.998" lower_limit="0.949" upper_limit="1.049"/>
                    <measurement group_id="O2" value="0.993" lower_limit="0.949" upper_limit="1.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RUL; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.057" lower_limit="0.954" upper_limit="1.172"/>
                    <measurement group_id="O2" value="0.982" lower_limit="0.917" upper_limit="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RUL; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.050" lower_limit="0.920" upper_limit="1.198"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.916" upper_limit="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LUL; D12 , n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" lower_limit="0.929" upper_limit="1.175"/>
                    <measurement group_id="O2" value="1.005" lower_limit="0.932" upper_limit="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LUL; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" lower_limit="0.913" upper_limit="1.282"/>
                    <measurement group_id="O2" value="1.025" lower_limit="0.942" upper_limit="1.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RML; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.045" lower_limit="0.861" upper_limit="1.268"/>
                    <measurement group_id="O2" value="0.887" lower_limit="0.779" upper_limit="1.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RML; D28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.076" lower_limit="0.872" upper_limit="1.328"/>
                    <measurement group_id="O2" value="0.906" lower_limit="0.810" upper_limit="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RLL; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" lower_limit="0.889" upper_limit="1.238"/>
                    <measurement group_id="O2" value="0.910" lower_limit="0.817" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; RLL; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.014" lower_limit="0.826" upper_limit="1.244"/>
                    <measurement group_id="O2" value="0.956" lower_limit="0.854" upper_limit="1.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LLL; D12, n =57, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.082" lower_limit="0.911" upper_limit="1.286"/>
                    <measurement group_id="O2" value="0.924" lower_limit="0.827" upper_limit="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Lobes; LLL; D28 ,n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.077" lower_limit="0.888" upper_limit="1.306"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.879" upper_limit="1.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" lower_limit="0.982" upper_limit="1.121"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.945" upper_limit="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.944" upper_limit="1.113"/>
                    <measurement group_id="O2" value="0.987" lower_limit="0.932" upper_limit="1.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" lower_limit="0.898" upper_limit="1.039"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.957" upper_limit="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.024" lower_limit="0.958" upper_limit="1.095"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.946" upper_limit="1.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" lower_limit="0.954" upper_limit="1.132"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.929" upper_limit="1.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.008" lower_limit="0.929" upper_limit="1.095"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.957" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" lower_limit="0.937" upper_limit="1.105"/>
                    <measurement group_id="O2" value="0.926" lower_limit="0.861" upper_limit="0.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.013" lower_limit="0.915" upper_limit="1.121"/>
                    <measurement group_id="O2" value="0.935" lower_limit="0.879" upper_limit="0.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" lower_limit="0.898" upper_limit="1.057"/>
                    <measurement group_id="O2" value="1.021" lower_limit="0.955" upper_limit="1.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.032" lower_limit="0.947" upper_limit="1.126"/>
                    <measurement group_id="O2" value="0.936" lower_limit="0.875" upper_limit="1.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.884" upper_limit="1.094"/>
                    <measurement group_id="O2" value="0.952" lower_limit="0.892" upper_limit="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.953" lower_limit="0.868" upper_limit="1.047"/>
                    <measurement group_id="O2" value="1.033" lower_limit="0.986" upper_limit="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =57, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.032" lower_limit="0.940" upper_limit="1.133"/>
                    <measurement group_id="O2" value="0.956" lower_limit="0.895" upper_limit="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.027" lower_limit="0.919" upper_limit="1.147"/>
                    <measurement group_id="O2" value="0.968" lower_limit="0.904" upper_limit="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; D12D28 , n =54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" lower_limit="0.906" upper_limit="1.052"/>
                    <measurement group_id="O2" value="1.025" lower_limit="0.976" upper_limit="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal;Region; Upper; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.037" lower_limit="0.934" upper_limit="1.151"/>
                    <measurement group_id="O2" value="0.981" lower_limit="0.917" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Upper; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.049" lower_limit="0.909" upper_limit="1.211"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.924" upper_limit="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Lower; D12 , n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.061" lower_limit="0.911" upper_limit="1.235"/>
                    <measurement group_id="O2" value="0.921" lower_limit="0.830" upper_limit="1.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Lower; D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.037" lower_limit="0.867" upper_limit="1.241"/>
                    <measurement group_id="O2" value="0.977" lower_limit="0.876" upper_limit="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region;Central; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.006" lower_limit="0.972" upper_limit="1.042"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.970" upper_limit="1.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal;Region; Cetral; D28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.968" upper_limit="1.049"/>
                    <measurement group_id="O2" value="0.993" lower_limit="0.973" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Distal; D12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.048" lower_limit="0.930" upper_limit="1.182"/>
                    <measurement group_id="O2" value="0.947" lower_limit="0.876" upper_limit="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Distal D28 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.041" lower_limit="0.891" upper_limit="1.215"/>
                    <measurement group_id="O2" value="0.983" lower_limit="0.905" upper_limit="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region;Total; D12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.014" lower_limit="0.968" upper_limit="1.062"/>
                    <measurement group_id="O2" value="0.979" lower_limit="0.954" upper_limit="1.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Longitudinal; Region; Total; D28 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.955" upper_limit="1.061"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.963" upper_limit="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033" lower_limit="0.969" upper_limit="1.102"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.940" upper_limit="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.945" upper_limit="1.111"/>
                    <measurement group_id="O2" value="0.983" lower_limit="0.929" upper_limit="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.915" upper_limit="1.055"/>
                    <measurement group_id="O2" value="1.006" lower_limit="0.964" upper_limit="1.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.030" lower_limit="0.949" upper_limit="1.118"/>
                    <measurement group_id="O2" value="0.951" lower_limit="0.894" upper_limit="1.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" lower_limit="0.904" upper_limit="1.099"/>
                    <measurement group_id="O2" value="0.963" lower_limit="0.903" upper_limit="1.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964" lower_limit="0.889" upper_limit="1.045"/>
                    <measurement group_id="O2" value="1.025" lower_limit="0.985" upper_limit="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Central; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.973" upper_limit="1.037"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.976" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.007" lower_limit="0.971" upper_limit="1.044"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.977" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region Central; D12D28 ,n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.980" upper_limit="1.022"/>
                    <measurement group_id="O2" value="1.003" lower_limit="0.991" upper_limit="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.030" lower_limit="0.961" upper_limit="1.105"/>
                    <measurement group_id="O2" value="0.969" lower_limit="0.918" upper_limit="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.010" lower_limit="0.927" upper_limit="1.100"/>
                    <measurement group_id="O2" value="0.973" lower_limit="0.919" upper_limit="1.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Distal; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.906" upper_limit="1.04"/>
                    <measurement group_id="O2" value="1.016" lower_limit="0.978" upper_limit="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Total; SCRD12 , n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.010" lower_limit="0.974" upper_limit="1.046"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.967" upper_limit="1.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.006" lower_limit="0.966" upper_limit="1.047"/>
                    <measurement group_id="O2" value="0.990" lower_limit="0.968" upper_limit="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed;Region;Total; D12D28 , n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.993" lower_limit="0.968" upper_limit="1.019"/>
                    <measurement group_id="O2" value="1.005" lower_limit="0.990" upper_limit="1.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>59.55</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>(FRC; Longitudinal; Lobes; RUL; D12, The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.01</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>(FRC; Longitudinal; Lobes; RUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>82.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LUL; D12, The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.22</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>46.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RML; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.30</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RML; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>92.60</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.01</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; RLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>58.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Lobes; LLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>67.37</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.35</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.86</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.18</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>91.94</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>55.32</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.17</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.57</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>79.13</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.54</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>71.94</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>85.30</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>82.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>72.55</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal;Region; Upper; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Upper; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>78.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Lower; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Lower; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>91.11</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region;Central; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>89.30</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal;Region; Cetral; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>74.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Distal; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.25</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Distal D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region;Total; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>91.54</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>FRC; Longitudinal; Region; Total; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>68.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.19</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.74</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.83</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>79.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Central; SCRD12 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>47.62</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>71.55</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Bayesian repeated measures model</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>93.68</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.58</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>56.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>13.08</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>52.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>60.75</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LUL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.23</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LUL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.14</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RML; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>38.43</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RML; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>25.21</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.73</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; RLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LLL; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Lobes; LLL; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>4.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>30.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>80.34</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>25.65</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>24.36</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.45</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.95</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>14.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>80.61</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>3.30</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD12.The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>42.22</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; D12D28The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.38</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.39</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>23.27</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Upper; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>57.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Upper; D28.The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Lower; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>70.73</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Lower; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>25.61</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Central; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>44.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Cetral; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>10.14</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Distal; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>62.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Distal D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>11.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Total; D12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>51.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Longitudinal; Region; Total; D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.54</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>30.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>73.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>4.64</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model.</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>42.13</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>93.33</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>27.33</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>34.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>58.42</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>5.93</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>35.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.41</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>13.52</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.84</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Total; SCRD28 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>78.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
        <description>iRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Imaging Airways Resistance ( iRaw) Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
          <description>iRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>Kilopascal (Kpa)*s/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" lower_limit="0.620" upper_limit="1.330"/>
                    <measurement group_id="O2" value="0.948" lower_limit="0.693" upper_limit="1.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.849" lower_limit="0.529" upper_limit="1.362"/>
                    <measurement group_id="O2" value="0.958" lower_limit="0.701" upper_limit="1.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" lower_limit="0.715" upper_limit="1.510"/>
                    <measurement group_id="O2" value="0.898" lower_limit="0.697" upper_limit="1.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.982" lower_limit="0.687" upper_limit="1.403"/>
                    <measurement group_id="O2" value="0.946" lower_limit="0.706" upper_limit="1.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.937" lower_limit="0.620" upper_limit="1.417"/>
                    <measurement group_id="O2" value="0.820" lower_limit="0.568" upper_limit="1.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.842" lower_limit="0.603" upper_limit="1.176"/>
                    <measurement group_id="O2" value="0.934" lower_limit="0.703" upper_limit="1.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =53, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.022" lower_limit="0.667" upper_limit="1.568"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.656" upper_limit="1.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.378" lower_limit="0.865" upper_limit="2.196"/>
                    <measurement group_id="O2" value="0.886" lower_limit="0.632" upper_limit="1.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.027" lower_limit="0.692" upper_limit="1.523"/>
                    <measurement group_id="O2" value="1.198" lower_limit="0.811" upper_limit="1.769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.100" lower_limit="0.705" upper_limit="1.716"/>
                    <measurement group_id="O2" value="1.043" lower_limit="0.673" upper_limit="1.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" lower_limit="1.011" upper_limit="2.237"/>
                    <measurement group_id="O2" value="1.044" lower_limit="0.728" upper_limit="1.497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.289" lower_limit="0.953" upper_limit="1.745"/>
                    <measurement group_id="O2" value="1.126" lower_limit="0.773" upper_limit="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.781" lower_limit="0.522" upper_limit="1.167"/>
                    <measurement group_id="O2" value="0.738" lower_limit="0.491" upper_limit="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.949" lower_limit="0.637" upper_limit="1.414"/>
                    <measurement group_id="O2" value="0.818" lower_limit="0.546" upper_limit="1.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.051" lower_limit="0.818" upper_limit="1.350"/>
                    <measurement group_id="O2" value="1.012" lower_limit="0.700" upper_limit="1.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.934" lower_limit="0.656" upper_limit="1.329"/>
                    <measurement group_id="O2" value="0.960" lower_limit="0.735" upper_limit="1.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.940" lower_limit="0.629" upper_limit="1.404"/>
                    <measurement group_id="O2" value="0.887" lower_limit="0.643" upper_limit="1.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.869" lower_limit="0.617" upper_limit="1.223"/>
                    <measurement group_id="O2" value="1.127" lower_limit="0.834" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.845" lower_limit="0.543" upper_limit="1.314"/>
                    <measurement group_id="O2" value="0.821" lower_limit="0.531" upper_limit="1.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.215" lower_limit="0.835" upper_limit="1.766"/>
                    <measurement group_id="O2" value="0.868" lower_limit="0.606" upper_limit="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.113" lower_limit="0.887" upper_limit="1.396"/>
                    <measurement group_id="O2" value="1.193" lower_limit="0.805" upper_limit="1.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.104" lower_limit="0.832" upper_limit="1.464"/>
                    <measurement group_id="O2" value="0.933" lower_limit="0.769" upper_limit="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.079" lower_limit="0.794" upper_limit="1.465"/>
                    <measurement group_id="O2" value="0.950" lower_limit="0.810" upper_limit="1.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.033" lower_limit="0.851" upper_limit="1.253"/>
                    <measurement group_id="O2" value="1.010" lower_limit="0.854" upper_limit="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.800" lower_limit="0.546" upper_limit="1.174"/>
                    <measurement group_id="O2" value="0.859" lower_limit="0.600" upper_limit="1.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.993" lower_limit="0.675" upper_limit="1.459"/>
                    <measurement group_id="O2" value="0.873" lower_limit="0.636" upper_limit="1.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.887" lower_limit="0.670" upper_limit="1.175"/>
                    <measurement group_id="O2" value="1.220" lower_limit="0.890" upper_limit="1.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.006" lower_limit="0.760" upper_limit="1.333"/>
                    <measurement group_id="O2" value="0.919" lower_limit="0.738" upper_limit="1.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.036" lower_limit="0.758" upper_limit="1.417"/>
                    <measurement group_id="O2" value="0.922" lower_limit="0.750" upper_limit="1.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.820" upper_limit="1.220"/>
                    <measurement group_id="O2" value="1.066" lower_limit="0.875" upper_limit="1.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.843" lower_limit="0.677" upper_limit="1.049"/>
                    <measurement group_id="O2" value="0.978" lower_limit="0.810" upper_limit="1.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.929" lower_limit="0.714" upper_limit="1.210"/>
                    <measurement group_id="O2" value="1.019" lower_limit="0.826" upper_limit="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.152" lower_limit="0.953" upper_limit="1.391"/>
                    <measurement group_id="O2" value="0.901" lower_limit="0.759" upper_limit="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.879" lower_limit="0.717" upper_limit="1.077"/>
                    <measurement group_id="O2" value="0.979" lower_limit="0.829" upper_limit="1.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.922" lower_limit="0.726" upper_limit="1.173"/>
                    <measurement group_id="O2" value="0.886" lower_limit="0.687" upper_limit="1.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.025" lower_limit="0.857" upper_limit="1.226"/>
                    <measurement group_id="O2" value="0.894" lower_limit="0.750" upper_limit="1.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.076" lower_limit="0.834" upper_limit="1.388"/>
                    <measurement group_id="O2" value="1.349" lower_limit="1.001" upper_limit="1.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" lower_limit="0.722" upper_limit="1.355"/>
                    <measurement group_id="O2" value="1.220" lower_limit="0.909" upper_limit="1.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.102" lower_limit="0.869" upper_limit="1.397"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.771" upper_limit="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.848" lower_limit="0.587" upper_limit="1.225"/>
                    <measurement group_id="O2" value="1.143" lower_limit="0.900" upper_limit="1.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" lower_limit="0.688" upper_limit="1.352"/>
                    <measurement group_id="O2" value="1.122" lower_limit="0.868" upper_limit="1.452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.208" lower_limit="0.941" upper_limit="1.550"/>
                    <measurement group_id="O2" value="0.927" lower_limit="0.775" upper_limit="1.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.813" lower_limit="0.605" upper_limit="1.093"/>
                    <measurement group_id="O2" value="1.139" lower_limit="0.893" upper_limit="1.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.958" lower_limit="0.682" upper_limit="1.346"/>
                    <measurement group_id="O2" value="0.987" lower_limit="0.758" upper_limit="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.313" lower_limit="1.022" upper_limit="1.686"/>
                    <measurement group_id="O2" value="0.829" lower_limit="0.670" upper_limit="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.913" lower_limit="0.754" upper_limit="1.106"/>
                    <measurement group_id="O2" value="1.103" lower_limit="0.911" upper_limit="1.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.958" lower_limit="0.751" upper_limit="1.222"/>
                    <measurement group_id="O2" value="0.957" lower_limit="0.764" upper_limit="1.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.067" lower_limit="0.896" upper_limit="1.270"/>
                    <measurement group_id="O2" value="0.885" lower_limit="0.752" upper_limit="1.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.850" lower_limit="0.621" upper_limit="1.163"/>
                    <measurement group_id="O2" value="1.116" lower_limit="0.897" upper_limit="1.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.953" lower_limit="0.676" upper_limit="1.344"/>
                    <measurement group_id="O2" value="1.056" lower_limit="0.827" upper_limit="1.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.269" lower_limit="1.021" upper_limit="1.578"/>
                    <measurement group_id="O2" value="0.862" lower_limit="0.723" upper_limit="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" lower_limit="0.841" upper_limit="1.095"/>
                    <measurement group_id="O2" value="1.007" lower_limit="0.937" upper_limit="1.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" lower_limit="0.838" upper_limit="1.136"/>
                    <measurement group_id="O2" value="1.000" lower_limit="0.933" upper_limit="1.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.039" lower_limit="0.945" upper_limit="1.142"/>
                    <measurement group_id="O2" value="0.981" lower_limit="0.932" upper_limit="1.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.889" lower_limit="0.680" upper_limit="1.161"/>
                    <measurement group_id="O2" value="1.116" lower_limit="0.913" upper_limit="1.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.945" lower_limit="0.698" upper_limit="1.279"/>
                    <measurement group_id="O2" value="0.976" lower_limit="0.793" upper_limit="1.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.189" lower_limit="1.000" upper_limit="1.414"/>
                    <measurement group_id="O2" value="0.838" lower_limit="0.719" upper_limit="0.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.891" lower_limit="0.762" upper_limit="1.042"/>
                    <measurement group_id="O2" value="1.061" lower_limit="0.937" upper_limit="1.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.956" lower_limit="0.781" upper_limit="1.171"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.861" upper_limit="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.133" lower_limit="0.990" upper_limit="1.296"/>
                    <measurement group_id="O2" value="0.904" lower_limit="0.816" upper_limit="1.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>60.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>51.75</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>65.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>89.98</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>43.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>36.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.74</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>50.74</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>72.81</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.41</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.07</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>69.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>73.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>54.22</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.46</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>21.45</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Upper; D12D28 . The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>69.91</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>44.05</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.93</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region; Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.11</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>85.41</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>54.73</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>72.31</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>15.05</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>84.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>92.24</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.42</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.05</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.40</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>97.39</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>16.02</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.69</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>90.22</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.64</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>20.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>55.06</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>5.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.82</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>93.00</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.64</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>50.71</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.52</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>3.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.39</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>93.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>3.79</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>36.75</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.32</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>18.91</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>47.35</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>78.00</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.65</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>58.48</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.64</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.No</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.90</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.03</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.19</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
        <description>siRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Imaging Specific Airways Resistance: siRaw Measured at FRC and TLC Scan Conditions, Presented in Scan Trimmed Scan Types, Measured in 5 Lobes and 5 Regions at Screening, Day 12 and Day 28</title>
          <description>siRaw was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. It was measured at functional residual volume (FRC) and total lung capacity (TLC). Data was collected at each time point for scan trimmed pairs: SCRD12, SCRD28 &amp; D12D28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For SCRD12 &amp; SCRD28 scan trimmed pairs the baseline is screening, for D12D28 scan trimmed pair the baseline is D12. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>Kpa*s</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD12 , n =54, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.896" lower_limit="0.613" upper_limit="1.310"/>
                    <measurement group_id="O2" value="0.908" lower_limit="0.669" upper_limit="1.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.829" lower_limit="0.516" upper_limit="1.333"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.757" upper_limit="1.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RUL; D12D28 , n =51, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" lower_limit="0.712" upper_limit="1.505"/>
                    <measurement group_id="O2" value="0.926" lower_limit="0.720" upper_limit="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.957" lower_limit="0.671" upper_limit="1.365"/>
                    <measurement group_id="O2" value="0.944" lower_limit="0.715" upper_limit="1.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.919" lower_limit="0.610" upper_limit="1.383"/>
                    <measurement group_id="O2" value="0.834" lower_limit="0.585" upper_limit="1.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.849" lower_limit="0.608" upper_limit="1.184"/>
                    <measurement group_id="O2" value="0.948" lower_limit="0.717" upper_limit="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD12 , n =52, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" lower_limit="0.655" upper_limit="1.553"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.669" upper_limit="1.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; SCRD28 , n=53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.349" lower_limit="0.856" upper_limit="2.125"/>
                    <measurement group_id="O2" value="0.904" lower_limit="0.649" upper_limit="1.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RML; D12D28 , n =52, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.028" lower_limit="0.695" upper_limit="1.521"/>
                    <measurement group_id="O2" value="1.213" lower_limit="0.818" upper_limit="1.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD12 , n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.078" lower_limit="0.687" upper_limit="1.691"/>
                    <measurement group_id="O2" value="1.046" lower_limit="0.671" upper_limit="1.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.468" lower_limit="0.990" upper_limit="2.177"/>
                    <measurement group_id="O2" value="1.053" lower_limit="0.736" upper_limit="1.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; RLL; D12D28 , n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.284" lower_limit="0.940" upper_limit="1.754"/>
                    <measurement group_id="O2" value="1.130" lower_limit="0.778" upper_limit="1.641"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD12 , n =53, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.755" lower_limit="0.506" upper_limit="1.127"/>
                    <measurement group_id="O2" value="0.725" lower_limit="0.479" upper_limit="1.098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; SCRD28 , n=54, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.930" lower_limit="0.629" upper_limit="1.375"/>
                    <measurement group_id="O2" value="0.811" lower_limit="0.539" upper_limit="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Lobes; LLL; D12D28 , n =51, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.063" lower_limit="0.829" upper_limit="1.362"/>
                    <measurement group_id="O2" value="1.017" lower_limit="0.702" upper_limit="1.476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.915" lower_limit="0.645" upper_limit="1.300"/>
                    <measurement group_id="O2" value="0.956" lower_limit="0.740" upper_limit="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.919" lower_limit="0.617" upper_limit="1.370"/>
                    <measurement group_id="O2" value="0.898" lower_limit="0.659" upper_limit="1.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.870" lower_limit="0.620" upper_limit="1.220"/>
                    <measurement group_id="O2" value="1.142" lower_limit="0.849" upper_limit="1.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; SCRD12 ,n =54, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.825" lower_limit="0.530" upper_limit="1.283"/>
                    <measurement group_id="O2" value="0.816" lower_limit="0.524" upper_limit="1.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region; Lower; SCRD28 ,n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.188" lower_limit="0.821" upper_limit="1.718"/>
                    <measurement group_id="O2" value="0.869" lower_limit="0.606" upper_limit="1.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed; Region;Lower; D12D28 ,n =52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.114" lower_limit="0.881" upper_limit="1.409"/>
                    <measurement group_id="O2" value="1.200" lower_limit="0.810" upper_limit="1.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.077" lower_limit="0.813" upper_limit="1.425"/>
                    <measurement group_id="O2" value="0.928" lower_limit="0.762" upper_limit="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.053" lower_limit="0.777" upper_limit="1.427"/>
                    <measurement group_id="O2" value="0.957" lower_limit="0.817" upper_limit="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.035" lower_limit="0.851" upper_limit="1.259"/>
                    <measurement group_id="O2" value="1.022" lower_limit="0.863" upper_limit="1.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.781" lower_limit="0.533" upper_limit="1.144"/>
                    <measurement group_id="O2" value="0.854" lower_limit="0.598" upper_limit="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.969" lower_limit="0.661" upper_limit="1.421"/>
                    <measurement group_id="O2" value="0.880" lower_limit="0.645" upper_limit="1.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.890" lower_limit="0.672" upper_limit="1.179"/>
                    <measurement group_id="O2" value="1.234" lower_limit="0.903" upper_limit="1.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.982" lower_limit="0.741" upper_limit="1.300"/>
                    <measurement group_id="O2" value="0.914" lower_limit="0.732" upper_limit="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.012" lower_limit="0.742" upper_limit="1.378"/>
                    <measurement group_id="O2" value="0.929" lower_limit="0.760" upper_limit="1.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC; Scan Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.003" lower_limit="0.821" upper_limit="1.225"/>
                    <measurement group_id="O2" value="1.078" lower_limit="0.886" upper_limit="1.311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.848" lower_limit="0.686" upper_limit="1.049"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.816" upper_limit="1.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.934" lower_limit="0.725" upper_limit="1.203"/>
                    <measurement group_id="O2" value="1.043" lower_limit="0.846" upper_limit="1.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.142" lower_limit="0.945" upper_limit="1.379"/>
                    <measurement group_id="O2" value="0.903" lower_limit="0.757" upper_limit="1.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.880" lower_limit="0.721" upper_limit="1.074"/>
                    <measurement group_id="O2" value="0.977" lower_limit="0.832" upper_limit="1.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.926" lower_limit="0.736" upper_limit="1.165"/>
                    <measurement group_id="O2" value="0.885" lower_limit="0.690" upper_limit="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LUL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.023" lower_limit="0.856" upper_limit="1.221"/>
                    <measurement group_id="O2" value="0.896" lower_limit="0.751" upper_limit="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD12 , n =57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.073" lower_limit="0.829" upper_limit="1.390"/>
                    <measurement group_id="O2" value="1.343" lower_limit="0.995" upper_limit="1.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; SCRD28 , n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" lower_limit="0.727" upper_limit="1.324"/>
                    <measurement group_id="O2" value="1.238" lower_limit="0.921" upper_limit="1.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RML; D12D28 , n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.093" lower_limit="0.867" upper_limit="1.377"/>
                    <measurement group_id="O2" value="1.010" lower_limit="0.782" upper_limit="1.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.854" lower_limit="0.595" upper_limit="1.226"/>
                    <measurement group_id="O2" value="1.149" lower_limit="0.910" upper_limit="1.449"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.964" lower_limit="0.695" upper_limit="1.337"/>
                    <measurement group_id="O2" value="1.134" lower_limit="0.887" upper_limit="1.450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; RLL; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.192" lower_limit="0.937" upper_limit="1.518"/>
                    <measurement group_id="O2" value="0.935" lower_limit="0.782" upper_limit="1.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD12 , n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.820" lower_limit="0.617" upper_limit="1.089"/>
                    <measurement group_id="O2" value="1.126" lower_limit="0.891" upper_limit="1.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; SCRD28 , n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.960" lower_limit="0.690" upper_limit="1.335"/>
                    <measurement group_id="O2" value="0.985" lower_limit="0.760" upper_limit="1.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Lobes; LLL; D12D28 , n=52, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.302" lower_limit="1.013" upper_limit="1.674"/>
                    <measurement group_id="O2" value="0.839" lower_limit="0.679" upper_limit="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.917" lower_limit="0.760" upper_limit="1.106"/>
                    <measurement group_id="O2" value="1.100" lower_limit="0.912" upper_limit="1.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.961" lower_limit="0.762" upper_limit="1.213"/>
                    <measurement group_id="O2" value="0.957" lower_limit="0.767" upper_limit="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Upper; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.060" lower_limit="0.891" upper_limit="1.262"/>
                    <measurement group_id="O2" value="0.888" lower_limit="0.755" upper_limit="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.856" lower_limit="0.631" upper_limit="1.162"/>
                    <measurement group_id="O2" value="1.112" lower_limit="0.900" upper_limit="1.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region; Lower; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" lower_limit="0.683" upper_limit="1.332"/>
                    <measurement group_id="O2" value="1.061" lower_limit="0.838" upper_limit="1.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed; Region;Lower; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.256" lower_limit="1.015" upper_limit="1.553"/>
                    <measurement group_id="O2" value="0.871" lower_limit="0.731" upper_limit="1.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Central; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.963" lower_limit="0.850" upper_limit="1.092"/>
                    <measurement group_id="O2" value="1.004" lower_limit="0.931" upper_limit="1.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region Central; SCRD28 ,n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.977" lower_limit="0.852" upper_limit="1.121"/>
                    <measurement group_id="O2" value="1.002" lower_limit="0.927" upper_limit="1.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region Central; D12D28 ,n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.032" lower_limit="0.939" upper_limit="1.135"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.941" upper_limit="1.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Distal; SCRD12 ,n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.892" lower_limit="0.688" upper_limit="1.157"/>
                    <measurement group_id="O2" value="1.112" lower_limit="0.915" upper_limit="1.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region; Distal; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.946" lower_limit="0.705" upper_limit="1.270"/>
                    <measurement group_id="O2" value="0.978" lower_limit="0.800" upper_limit="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Distal; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.181" lower_limit="0.996" upper_limit="1.401"/>
                    <measurement group_id="O2" value="0.844" lower_limit="0.724" upper_limit="0.983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed; Region;Total; SCRD12 , n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" lower_limit="0.771" upper_limit="1.038"/>
                    <measurement group_id="O2" value="1.058" lower_limit="0.938" upper_limit="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC;Scan Trimmed;Region;Total; SCRD28 , n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.958" lower_limit="0.793" upper_limit="1.158"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.867" upper_limit="1.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC; Scan Trimmed;Region;Total; D12D28 , n =53, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.125" lower_limit="0.986" upper_limit="1.285"/>
                    <measurement group_id="O2" value="0.911" lower_limit="0.822" upper_limit="1.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>67.19</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>44.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>59.90</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>70.12</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>83.98</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>34.93</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.45</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>95.35</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>50.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>59.37</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>70.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.71</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>65.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>71.95</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.28</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>61.06</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>18.05</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>61.12</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>64.40</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>38.12</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>91.00</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>94.52</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>82.11</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region Central; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.10</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>65.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>11.46</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>77.20</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>87.35</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>FRC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>56.53</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures random effect</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>FRC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>7.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.50</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>55.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>96.49</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>14.54</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.85</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>85.77</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LUL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>8.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>14.80</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>45.69</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RML; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.94</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>13.92</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.40</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; RLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>41.25</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.20</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Lobes; LLL; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>3.49</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; SCRD12 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>73.09</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>92.41</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Upper; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>23.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters.Unstructured covariance matrix fitted, accounting for correlation within region and visit</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.56</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region; Lower; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed; Region;Lower; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>14.50</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Central; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>30.26</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region Central; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>62.84</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region Central; D12D28 .The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.06</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Distal; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>49.97</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region; Distal; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>99.43</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Distal; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.17</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed; Region;Total; SCRD12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>49.78</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>TLC;Scan Trimmed;Region;Total; SCRD28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>98.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>TLC; Scan Trimmed;Region;Total; D12D28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28</title>
        <description>Change from Baseline in lung lobar volumes was measured at functional residual volume (FRC) and total lung capacity (TLC) scan conditions. Data was collected at longitudinal time points: Day 12 &amp; Day 28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points the baseline is screening. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lung Lobar Volumes Measured at FRC and TLC Scan Conditions, Presented in Longitudinal Scan Types, Measured in 5 Lobes and 5 Regions at Day 12 and Day 28</title>
          <description>Change from Baseline in lung lobar volumes was measured at functional residual volume (FRC) and total lung capacity (TLC) scan conditions. Data was collected at longitudinal time points: Day 12 &amp; Day 28. At each time point it was measure at 5 lobes (RUL, LUL, RML, RLL &amp; LLL) and 5 Regions (Upper, Lower, Central, Distal &amp; Total). For longitudinal time points the baseline is screening. Change from baseline is the post-Baseline value minus the Baseline value. Only particpants available at the specified time point were analysed (represented by n=X1, X2 in the category title).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC Lobes; RUL; Day 12, n =56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.983" lower_limit="0.953" upper_limit="1.014"/>
                    <measurement group_id="O2" value="0.995" lower_limit="0.964" upper_limit="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; RUL Day 28, n =56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.977" lower_limit="0.949" upper_limit="1.005"/>
                    <measurement group_id="O2" value="1.017" lower_limit="0.985" upper_limit="1.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; LUL Day 12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.974" lower_limit="0.943" upper_limit="1.007"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.964" upper_limit="1.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes;LUL Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.953" upper_limit="1.009"/>
                    <measurement group_id="O2" value="1.017" lower_limit="0.978" upper_limit="1.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; RML Day 12, n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.981" lower_limit="0.943" upper_limit="1.022"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.959" upper_limit="1.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; RML Day 28, n =56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" lower_limit="0.943" upper_limit="1.002"/>
                    <measurement group_id="O2" value="0.996" lower_limit="0.963" upper_limit="1.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; RLL Day 12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.977" lower_limit="0.933" upper_limit="1.024"/>
                    <measurement group_id="O2" value="1.004" lower_limit="0.964" upper_limit="1.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; RLL Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.972" lower_limit="0.939" upper_limit="1.007"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.968" upper_limit="1.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; LLL Day 12, n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.968" lower_limit="0.934" upper_limit="1.004"/>
                    <measurement group_id="O2" value="0.983" lower_limit="0.944" upper_limit="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Lobes; LLL Day 28, n =55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.979" lower_limit="0.948" upper_limit="1.010"/>
                    <measurement group_id="O2" value="0.991" lower_limit="0.950" upper_limit="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Upper Day 12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" lower_limit="0.950" upper_limit="1.011"/>
                    <measurement group_id="O2" value="0.996" lower_limit="0.966" upper_limit="1.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Upper Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.978" lower_limit="0.954" upper_limit="1.004"/>
                    <measurement group_id="O2" value="1.013" lower_limit="0.979" upper_limit="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Lower Day 12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.936" upper_limit="1.016"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.956" upper_limit="1.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Lower Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.945" upper_limit="1.007"/>
                    <measurement group_id="O2" value="1.001" lower_limit="0.962" upper_limit="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Total Day 12, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.975" lower_limit="0.944" upper_limit="1.007"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.964" upper_limit="1.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Region; Total Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" lower_limit="0.950" upper_limit="1.003"/>
                    <measurement group_id="O2" value="1.008" lower_limit="0.974" upper_limit="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RUL; Day 12, n =58, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" lower_limit="0.994" upper_limit="1.024"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.986" upper_limit="1.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RUL Day 28, n =56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.985" upper_limit="1.025"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.984" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; LUL Day 12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.989" upper_limit="1.014"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.984" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes;LUL Day 28, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.004" lower_limit="0.984" upper_limit="1.025"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.982" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RML Day 12, n =57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.998" lower_limit="0.975" upper_limit="1.021"/>
                    <measurement group_id="O2" value="0.988" lower_limit="0.970" upper_limit="1.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RML Day 28, n =56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.992" lower_limit="0.960" upper_limit="1.025"/>
                    <measurement group_id="O2" value="0.996" lower_limit="0.979" upper_limit="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RLL Day 12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.010" lower_limit="0.983" upper_limit="1.038"/>
                    <measurement group_id="O2" value="1.005" lower_limit="0.977" upper_limit="1.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; RLL Day 28, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.974" upper_limit="1.026"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.975" upper_limit="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; LLL Day 12, n =57, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.008" lower_limit="0.975" upper_limit="1.042"/>
                    <measurement group_id="O2" value="0.989" lower_limit="0.964" upper_limit="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lobes; LLL Day 28, n =55, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.977" upper_limit="1.028"/>
                    <measurement group_id="O2" value="0.996" lower_limit="0.968" upper_limit="1.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Upper Day 12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.993" upper_limit="1.017"/>
                    <measurement group_id="O2" value="0.997" lower_limit="0.985" upper_limit="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC UpperDay 28, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.004" lower_limit="0.984" upper_limit="1.023"/>
                    <measurement group_id="O2" value="0.999" lower_limit="0.985" upper_limit="1.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lower Day 12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.009" lower_limit="0.982" upper_limit="1.037"/>
                    <measurement group_id="O2" value="0.997" lower_limit="0.972" upper_limit="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Lower Day 28, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.978" upper_limit="1.024"/>
                    <measurement group_id="O2" value="1.003" lower_limit="0.973" upper_limit="1.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Total Day 12, n =58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.005" lower_limit="0.989" upper_limit="1.022"/>
                    <measurement group_id="O2" value="0.997" lower_limit="0.980" upper_limit="1.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Total Day 28, n =56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.002" lower_limit="0.982" upper_limit="1.022"/>
                    <measurement group_id="O2" value="1.001" lower_limit="0.981" upper_limit="1.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.51</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC Lobes; RUL; Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.21</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>FRC Lobes; RUL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>15.91</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Lobes; LUL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>6.73</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>FRC Lobes;LUL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>27.65</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Lobes; RML Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>12.19</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Lobes; RML Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>11.62</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>FRC Lobes; RLL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>7.66</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>FRC Lobes; RLL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.88</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Lobes; LLL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.28</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Lobes; LLL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>27.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC Region; Upper Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>9.83</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.No</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Region; Upper Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>21.87</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Region; Lower Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>18.58</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Region; Lower Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>22.28</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC Region; Total Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>10.86</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Region; Total Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>84.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Lobes; RUL; Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.78</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Lobes; RUL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>69.42</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Lobes; LUL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>62.63</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Lobes;LUL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>72.55</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Lobes; RML Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>36.28</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC Lobes; RML Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>47.44</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC Lobes; RLL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>22.99</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>TLC Lobes; RLL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>85.95</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Lobes; LLL Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>60.20</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC Lobes; LLL Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>81.34</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Upper Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>63.04</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC UpperDay 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>69.67</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC Lower Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>39.81</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>TLC Lower Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>73.01</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Total Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>48.97</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC Total Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment</title>
        <description>Imaging trachea length and diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length and diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Imaging Trachea Length and Diameter After 12 Days of Treatment and After 28 Days of Treatment</title>
          <description>Imaging trachea length and diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length and diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>Millimeter (mm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC Length Day 12, n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.886" spread="7.6043"/>
                    <measurement group_id="O2" value="0.517" spread="6.0882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Length Day 28, n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.434" spread="6.7887"/>
                    <measurement group_id="O2" value="0.485" spread="6.6552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Diameter Day 12, n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.247" spread="1.8777"/>
                    <measurement group_id="O2" value="0.059" spread="1.1657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Diameter Day 28, n=56, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.261" spread="1.8672"/>
                    <measurement group_id="O2" value="-0.047" spread="1.1522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Length Day 12, n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.295" spread="4.0608"/>
                    <measurement group_id="O2" value="-0.663" spread="3.8027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Length Day 28, n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.168" spread="4.5501"/>
                    <measurement group_id="O2" value="-0.495" spread="3.7295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Diameter Day 12, n=58, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.067" spread="1.0127"/>
                    <measurement group_id="O2" value="-0.056" spread="0.5098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Diameter Day 28, n=56, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" spread="1.0240"/>
                    <measurement group_id="O2" value="-0.082" spread="0.5579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>2.89</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Length Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>8.49</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC Length Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>86.21</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>FRC Diameter Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>75.20</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC Diameter Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>84.29</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Length Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>71.08</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Length Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>34.93</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Diameter Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>25.05</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is greater than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>TLC Diameter Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment</title>
        <description>Imaging trachea length/diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length/diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 12 and Day 28</time_frame>
        <population>ITT Population excluding the subject with a pacemaker.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 µg</title>
            <description>Participants received 1000 µg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Imaging Trachea Length/Diameter After 12 Days of Treatment and After 28 Days of Treatment</title>
          <description>Imaging trachea length/diameter was derived from HRCT to evaluate the effect of once daily inhaled dose of GSK2269557 on lung parameters. TLC is the volume in the lungs at maximal inflation and FRC is the volume in the lungs at the end-expiratory position. The Baseline for the assessment on Day 12 and Day 28 is the Screening value. Change from Baseline is the post-Baseline value minus the Baseline value. The change from Baseline data is presented for Day 12 and Day 28 for trachea length/diameter. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population excluding the subject with a pacemaker.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FRC Length/Diameter Day 12, n=56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.030" spread="0.7717"/>
                    <measurement group_id="O2" value="0.000" spread="0.5620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRC Length/Diameter Day 28, n=56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" spread="0.7469"/>
                    <measurement group_id="O2" value="0.059" spread="0.5169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Length/Diameter Day 12, n=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.024" spread="0.3602"/>
                    <measurement group_id="O2" value="-0.023" spread="0.2913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TLC Length/Diameter Day 28, n=5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.3715"/>
                    <measurement group_id="O2" value="-0.006" spread="0.2783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>28.51</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
            <estimate_desc>FRC Length/Diameter Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>32.15</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>FRC Length/Diameter Day 28. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>66.51</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>TLC Length/Diameter Day 12. The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>45.28</p_value>
            <p_value_desc>The data entered for the p-value represents the posterior probability that the true treatment ratio is less than 1. P-value is denoted in percentage.</p_value_desc>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Posterior Median Ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>TLC Length/Diameter Day 28 The data entered to the 95% confidence interval represents the 95% equi-tailed credible interval.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were collected from the start of study treatment until the follow-up contact.</description>
        <time_frame>From start of IP through the Study Phase (84 days post-dose) (assessed up to follow-up duration of approximately 100 days)</time_frame>
        <population>All Subjects Population: all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were collected from the start of study treatment until the follow-up contact.</description>
          <population>All Subjects Population: all randomized participants who received at least one dose of study treatment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Hematology Parameters</title>
        <description>Hematology parameter included Hematocrit (HCT), Hemoglobin (HB), Lymphocytes (LC), Platelet Count (PC), Total Neutrophils (TN), and White Blood Cell (WBC) count at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 Days)</time_frame>
        <population>All Subjects Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Hematology Parameters</title>
          <description>Hematology parameter included Hematocrit (HCT), Hemoglobin (HB), Lymphocytes (LC), Platelet Count (PC), Total Neutrophils (TN), and White Blood Cell (WBC) count at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>All Subjects Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High HCT Screening/Day 1, n=63, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HCT Day 12, n=60, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HCT Day 28, n=57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HCT Day 56, n=55, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HCT Day 84, n=49, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HCT Follow-up/Early Withdraw, n=54, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Day 12, n=60, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Day 28, n=57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Day 56, n=55, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Day 84, n=49, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HB Follow-up/Early Withdraw, n=54, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Screening/ Day 1, n=62, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Day 12, n=59, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Day 28, n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Day 56, n=54, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Day 84, n=48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low LC Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Screening/Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Day 12, n=58, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Day 28, n=57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Day 56, n=55, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Day 84, n=49, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High PC Follow-up/Early Withdraw, n=54, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Day 12, n=58, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Day 28, n=57, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Day 56, n=55, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Day 84, n=49, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low PC Follow-up/Early Withdraw, n=54, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Screening/ Day 1, n=62, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Day 12, n=59, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Day 28, n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Day 56, n=54, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Day 84, n=48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low TN Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Day 12, n=56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Day 28, n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Day 56, n=54, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Day 84, n=48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High WBC Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Day 12, n=56, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Day 28, n=56, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Day 56, n=54, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Day 84, n=48, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low WBC Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Clinical Chemistry Parameters</title>
        <description>Clinical Chemistry parameters included Alanine Amino Transferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Calcium (Ca), Glucose, Potassium (K), Sodium (Na), and Total Bilirubin (TBL) at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
        <population>All Subject Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Clinical Chemistry Parameters</title>
          <description>Clinical Chemistry parameters included Alanine Amino Transferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Calcium (Ca), Glucose, Potassium (K), Sodium (Na), and Total Bilirubin (TBL) at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, and at follow-up/Early withdrawal. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>All Subject Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High ALT Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALT Follow-up/Early Withdraw, n=53, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Albumin Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High ALP Follow-up/Early Withdraw, n=53, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High AST Follow-up/Early Withdraw, n=53, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Ca Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Ca Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Glucose Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Glucose Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Day 84, n=52, 550</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Potassium Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium V4 Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Potassium Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sodium Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Sodium Follow-up/Early Withdraw, n=53, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Day 28, n=58,60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Day 84, n=51, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High TBL Follow-up/Early Withdraw, n=53, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Vital Signs</title>
        <description>Vital signs included high and low diastolic and systolic blood presure (BP), and high and low heart rate (HR). Vital signs outside the range of potential clinical importance are presented at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline . Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
        <population>All Subject Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Vital Signs</title>
          <description>Vital signs included high and low diastolic and systolic blood presure (BP), and high and low heart rate (HR). Vital signs outside the range of potential clinical importance are presented at the indicated timepoints: Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline . Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>All Subject Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High DBP Screening/Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High DBP Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP V6 Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low DBP Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High SBP Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Screening/ V1 Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low SBP Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High HR Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Follow-up/Early Withdraw, n=55, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HR Any Visit Post Baseline, n=62, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)</title>
        <description>12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Clinically non-significant (CN) and Clinically significant (CS) abnormal ECG measurements are presented for Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Day 1, Day 12, Day 28, Day 56, Day 84 and at follow-up (approximately 100 days)</time_frame>
        <population>All Subject Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal 12-lead Electrocardiogram (ECG)</title>
          <description>12-lead ECG was obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QT interval corrected using the Fridericia's formula (QTcF). Clinically non-significant (CN) and Clinically significant (CS) abnormal ECG measurements are presented for Day 1, Day 12, Day 28, Day 56, Day 84, follow-up/Early withdrawal and at any visit post-baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>All Subject Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CN ECG Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Screening/ Day 1, n=63, 63</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Day 12, n=61, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Day 28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Day 56, n=55, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Day 84, n=52, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Follow-up/Early Withdraw, n=56, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Follow-up/Early Withdraw, n=56, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CN ECG Any Visit Post Baseline, n=63, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CS ECG Any Visit Post Baseline, n=63, 62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose</title>
        <description>Plasma samples were collected at pre-dose, 5 minutes (min), 3 hrs, and 24 hrs post-dose on Day 1. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Pharmacokinetic (PK) Population: all participants in the Safety Population for whom a PK sample was obtained and analyzed. Safety Population comprises of all participants who were randomized.</description>
        <time_frame>Pre-dose, 5 min, 3 hrs and 24 hrs</time_frame>
        <population>Pharmacokinetic (PK) Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Day 1 Plasma Concentration up to 24 Hours (Hrs) Post-dose</title>
          <description>Plasma samples were collected at pre-dose, 5 minutes (min), 3 hrs, and 24 hrs post-dose on Day 1. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Pharmacokinetic (PK) Population: all participants in the Safety Population for whom a PK sample was obtained and analyzed. Safety Population comprises of all participants who were randomized.</description>
          <population>Pharmacokinetic (PK) Population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0">Only 5 of the 61 values had not been imputed as zero; therefore, calculation of the SD would result in a potentially misleading value and hence is omitted from the data display (if &gt;30% of values are imputed then the SD will not be included).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 min, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.6" spread="520.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hrs, n=61</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553.7" spread="326.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hrs, n=20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="539.0" spread="482.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment</title>
        <description>Trough concentrations are presented for Pre-dose Day 12, Pre-dose Day 28, Pre-dose Day 56, and Pre-dose Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Pre-dose Day 12, Day 28, Day 56, and Day 84</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentration After 12 Days, 28 Days, 56 Days and 84 Days of Treatment</title>
          <description>Trough concentrations are presented for Pre-dose Day 12, Pre-dose Day 28, Pre-dose Day 56, and Pre-dose Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>PK Population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose Day 12, n=57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1001.8" spread="669.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day 28, n=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1028.8" spread="798.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day 56, n=55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1119.8" spread="1389.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-dose Day 84, n=54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="948.6" spread="1078.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second. A triplicate FEV1 measurement were taken daily in the morning before dose administration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28, and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Forced Expiratory Volume in One Second (FEV1) Measured Daily</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second. A triplicate FEV1 measurement were taken daily in the morning before dose administration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=55, 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.4" spread="43.07"/>
                    <measurement group_id="O2" value="-72.2" spread="41.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, n=46, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.3" spread="49.73"/>
                    <measurement group_id="O2" value="-22.7" spread="46.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.487</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-118.5</ci_lower_limit>
            <ci_upper_limit>115.3</ci_upper_limit>
            <estimate_desc>Day 28</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.816</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>60.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-73.3</ci_lower_limit>
            <ci_upper_limit>194.3</ci_upper_limit>
            <estimate_desc>Day 84</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily</title>
        <description>PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28, and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Peak Expiratory Flow (PEF) Measured Daily</title>
          <description>PEF is the maximal flow (or speed) achieved during the maximally forced expiration initiated at full inspiration. Baseline is defined as the assessment on Day 1 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84.Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=54, 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.12" spread="60.421"/>
                    <measurement group_id="O2" value="-4.76" spread="57.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, n=45, 53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="65.374"/>
                    <measurement group_id="O2" value="-0.85" spread="71.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment</title>
        <description>DLco is diffusing capacity o f the lungs for carbon monoxide and is defined as the extent to which oxygen passes from the air sacs of the lungs into the blood. KCO is the carbon monoxide transfer coefficient. It is an index of the efficiency of alveolar transfer of carbon monoxide. Baseline is defined as the assessment on Day 2 and percent change from Baseline is the post-Baseline value minus Baseline value/100. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Diffusion Capacity (DLco, Kco) After 28 Days and After 84 Days of Treatment</title>
          <description>DLco is diffusing capacity o f the lungs for carbon monoxide and is defined as the extent to which oxygen passes from the air sacs of the lungs into the blood. KCO is the carbon monoxide transfer coefficient. It is an index of the efficiency of alveolar transfer of carbon monoxide. Baseline is defined as the assessment on Day 2 and percent change from Baseline is the post-Baseline value minus Baseline value/100. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DLco Day 28, n=53, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.783" spread="9.3950"/>
                    <measurement group_id="O2" value="-0.687" spread="8.2655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DLco Day 84, n=45, 51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.385" spread="9.6016"/>
                    <measurement group_id="O2" value="0.560" spread="9.5434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kco Day 28, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.745" spread="9.7851"/>
                    <measurement group_id="O2" value="-0.875" spread="8.0041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kco Day 84, n=45, 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.367" spread="10.2835"/>
                    <measurement group_id="O2" value="-0.759" spread="8.7801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment</title>
        <description>TLC is the maximum amount of air that can fill the lungs. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lung Capacity (TLC) After 28 Days and After 84 Days of Treatment</title>
          <description>TLC is the maximum amount of air that can fill the lungs. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=53, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" lower_limit="-0.211" upper_limit="0.190"/>
                    <measurement group_id="O2" value="-0.155" lower_limit="-0.344" upper_limit="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, n=47, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.149" lower_limit="-0.462" upper_limit="0.163"/>
                    <measurement group_id="O2" value="-0.029" lower_limit="-0.320" upper_limit="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.151</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.144</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.420</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Day 28</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.305</ci_lower_limit>
            <ci_upper_limit>0.551</ci_upper_limit>
            <estimate_desc>Day 84</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment</title>
        <description>Residual volume is a lung volume representing the amount of air left in the lungs after a forced exhalation. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Residual Volume After 28 Days and After 84 Days of Treatment</title>
          <description>Residual volume is a lung volume representing the amount of air left in the lungs after a forced exhalation. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Note: values mentioned as 95% confidence interval below are in fact values of 95% credible interval.</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=53, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.157" lower_limit="-0.441" upper_limit="0.129"/>
                    <measurement group_id="O2" value="0.022" lower_limit="-0.249" upper_limit="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, =47, 54</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.113" lower_limit="-0.430" upper_limit="0.206"/>
                    <measurement group_id="O2" value="0.001" lower_limit="-0.299" upper_limit="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.817</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.216</ci_lower_limit>
            <ci_upper_limit>0.570</ci_upper_limit>
            <estimate_desc>Day 28</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.697</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.324</ci_lower_limit>
            <ci_upper_limit>0.549</ci_upper_limit>
            <estimate_desc>Day 84</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment</title>
        <description>Functional residual capacity is the volume of air present in the lungs at the end of passive expiration. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Functional Residual Capacity After 28 Days and After 84 Days of Treatment</title>
          <description>Functional residual capacity is the volume of air present in the lungs at the end of passive expiration. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=52, 59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0010" spread="0.86637"/>
                    <measurement group_id="O2" value="-0.0919" spread="0.92501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, =46, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2219" spread="1.06874"/>
                    <measurement group_id="O2" value="-0.0505" spread="1.41910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment</title>
        <description>sRaw is the measure of specific resistance. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Resistance (sRaw) After 28 Days and After 84 Days of Treatment</title>
          <description>sRaw is the measure of specific resistance. Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>KPa*s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n= 17, 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9734" spread="0.45833"/>
                    <measurement group_id="O2" value="0.8372" spread="0.49176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, n=11, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9949" spread="0.24484"/>
                    <measurement group_id="O2" value="0.8495" spread="0.39565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment</title>
        <description>Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).Note: values mentioned as 95% confidence interval below are in fact values of 95% Credible Interval.</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Specific Conductance (sGaw) After 28 Days and After 84 Days of Treatment</title>
          <description>Baseline is defined as the assessment on Day 2 and change from Baseline is the post-Baseline value minus Baseline value. Change from Baseline data is presented for Day 28 and Day 84. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).Note: values mentioned as 95% confidence interval below are in fact values of 95% Credible Interval.</description>
          <population>ITT Population</population>
          <units>1/KPA*S</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28, n=47, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" lower_limit="0.773" upper_limit="0.990"/>
                    <measurement group_id="O2" value="1.024" lower_limit="0.910" upper_limit="1.150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84, =40, 47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.965" lower_limit="0.860" upper_limit="1.083"/>
                    <measurement group_id="O2" value="1.075" lower_limit="0.967" upper_limit="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.965</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.171</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.988</ci_lower_limit>
            <ci_upper_limit>1.388</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.913</p_value>
            <method>Bayesian repeated measures model</method>
            <method_desc>Non-informative priors used for all modelling parameters. Unstructured covariance matrix fitted, accounting for correlation within region and visit.</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>1.114</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.953</ci_lower_limit>
            <ci_upper_limit>1.305</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84</title>
        <description>The chronic obstructive pulmonary disease (COPD) assessement test (CAT) and Modified Medical Research Council (MMRC) Dyspnea Scale were completed at the indicated timepoints: Baseline, Day 28 and Day 84. CAT and MMRC scales are prestned as: 1.I never cough/I cough all the time 2.I have no phelgm in my chest at all/My chest is completely full of phelgm 3. My chest does not feel tight at all/My chest feels very tight 4.Walk up hilll or stairs not breathless/Walk up hill or stairs very breathless 5. Not limited doing any home activities/Very limited doing any home activities 6. Confident leaving home/No confident leaving home 7. I sleep soundly/I don't sleep soundly because of my lung condition and 8. I have lots of energy/I have no energy at all. Baseline is defined as the assessment on Day 1. Score 0 indicates not troubled with breathlessness to 4:too breathless. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
        <time_frame>Baseline, Day 28 and Day 84</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Questionnaires CAT and MMRC Scale at Baseline, Day 28 and Day 84</title>
          <description>The chronic obstructive pulmonary disease (COPD) assessement test (CAT) and Modified Medical Research Council (MMRC) Dyspnea Scale were completed at the indicated timepoints: Baseline, Day 28 and Day 84. CAT and MMRC scales are prestned as: 1.I never cough/I cough all the time 2.I have no phelgm in my chest at all/My chest is completely full of phelgm 3. My chest does not feel tight at all/My chest feels very tight 4.Walk up hilll or stairs not breathless/Walk up hill or stairs very breathless 5. Not limited doing any home activities/Very limited doing any home activities 6. Confident leaving home/No confident leaving home 7. I sleep soundly/I don't sleep soundly because of my lung condition and 8. I have lots of energy/I have no energy at all. Baseline is defined as the assessment on Day 1. Score 0 indicates not troubled with breathlessness to 4:too breathless. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</description>
          <population>ITT Population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>never cough/cough all the time D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.16"/>
                    <measurement group_id="O2" value="-0.7" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>never cough/cough all the time D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.48"/>
                    <measurement group_id="O2" value="-0.7" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No phlegm/full of phlegm in chest D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.26"/>
                    <measurement group_id="O2" value="-0.3" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No phlegm/full of phlegm in chest D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.20"/>
                    <measurement group_id="O2" value="-0.6" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No tightness/very tight chest D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.30"/>
                    <measurement group_id="O2" value="-0.3" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No tightness/very tight chest D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.43"/>
                    <measurement group_id="O2" value="-0.3" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hill/stairs nobreathless/breathlessD28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.98"/>
                    <measurement group_id="O2" value="-0.5" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hill/stairs nobreathless/breathless D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.43"/>
                    <measurement group_id="O2" value="-0.3" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlimited/limited home activity D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.43"/>
                    <measurement group_id="O2" value="-0.3" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlimited/limited home activity D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.24"/>
                    <measurement group_id="O2" value="-0.1" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confident/not confident leave home D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.24"/>
                    <measurement group_id="O2" value="-0.1" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confident/not confident leave homeD84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.49"/>
                    <measurement group_id="O2" value="-0.3" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sound sleep/No sound sleep D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.11"/>
                    <measurement group_id="O2" value="-0.2" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sound sleep/No sound sleep D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.60"/>
                    <measurement group_id="O2" value="-0.3" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lot of energy/no energy D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.46"/>
                    <measurement group_id="O2" value="-0.3" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lot of energy/no energy D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.49"/>
                    <measurement group_id="O2" value="-0.3" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAT Total Score D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="6.05"/>
                    <measurement group_id="O2" value="-2.6" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CAT Total Score D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="7.16"/>
                    <measurement group_id="O2" value="-3.1" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMRC Dyspnoea Score D28, n=58, 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.75"/>
                    <measurement group_id="O2" value="-0.2" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMRC Dyspnoea Score D84, n=53, 55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.95"/>
                    <measurement group_id="O2" value="-0.3" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Failures</title>
        <description>Treatment failure types are presented as: recurrent exacerbations, prolonged treatment of current exacerbation (beyond 14 days), additional treatment with systemic / oral corticosteroids and / or antibiotics, and requirement for invasive mechanical ventilation.</description>
        <time_frame>13 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 1000 mcg</title>
            <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Failures</title>
          <description>Treatment failure types are presented as: recurrent exacerbations, prolonged treatment of current exacerbation (beyond 14 days), additional treatment with systemic / oral corticosteroids and / or antibiotics, and requirement for invasive mechanical ventilation.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recurrent exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prolonged Treatment of current exacerbation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>continuation of treatment with SOC/antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional treatment with SOC/antibiotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Requirement of invasive mechanical ventilation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication up to approximately 100 days.</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
        <group group_id="E2">
          <title>GSK2269557 1000 mcg</title>
          <description>Participants received 1000 mcg of GSK2269557 two inhalations per day administered via a dry powder inhaler for a duration of 84 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

